Wird geladen...
Bumetanide for autism: Open‐label trial in six children
AIM: Bumetanide, a diuretic agent, that reduces intracellular chloride—thereby reinforcing GABAergic inhibition—has been reported to improve core symptoms of autism in children. Given the positive results reported from French trials of bumetanide in children with autism, we decided to evaluate its e...
Gespeichert in:
| Veröffentlicht in: | Acta Paediatr |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
John Wiley and Sons Inc.
2021
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8248373/ https://ncbi.nlm.nih.gov/pubmed/33336381 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/apa.15723 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|